Patents by Inventor Jayraj Dilipbhai Aradhye

Jayraj Dilipbhai Aradhye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic antiestrogens
    Patent number: 11465990
    Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: October 11, 2022
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ranjan Kumar Pal, Amit Pravinbhai Sedani, Kaushikkumar Dhanjibhai Prajapati, Dijixa Pinakin Rana, Sandeep Pankajbhai Pathak, Japan Nitinkumar Desai, Jayraj Dilipbhai Aradhye, Bhavesh Mohanbhai Panchal, Indraneel Ghosh, Trinadha Rao Chitturi
  • SELECTIVE ESTROGEN RECEPTOR DEGRADER
    Publication number: 20210261534
    Abstract: A selective estrogen receptor degrader (SERD), a compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, or pharmaceutically acceptable salts thereof. Also provided are processes for their preparation. Also provided for is the use of these compounds for the treatment of diseases which are related to modulation of estrogen receptors, such as ER-positive breast cancer.
    Type: Application
    Filed: May 5, 2021
    Publication date: August 26, 2021
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Ranjan Kumar PAL, Biswajit SAMANTA, Jayraj Dilipbhai ARADHYE, Sandeep Pankajkumar PATHAK, Kaushik Dhanjibhai PRAJAPATI, Bhavesh Mohanbhai PANCHAL, Trinadha Rao CHITTURI
  • Selective estrogen receptor degrader
    Patent number: 11014915
    Abstract: A selective estrogen receptor degrader (SERD), a compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, or pharmaceutically acceptable salts thereof. Also provided are processes for their preparation. Also provided for is the use of these compounds for the treatment of diseases which are related to modulation of estrogen receptors, such as ER-positive breast cancer.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: May 25, 2021
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Rajan Kumar Pal, Biswajit Samanta, Jayraj Dilipbhai Aradhye, Sandeep Pankajkumar Pathak, Kaushik Dhanjibhai Prajapati, Bhavesh Mohanbhai Panchal, Trinadha Rao Chitturi
  • NOVEL HETEROCYCLIC ANTIESTROGENS
    Publication number: 20210053947
    Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.
    Type: Application
    Filed: October 28, 2020
    Publication date: February 25, 2021
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Rajan Kumar PAL, Amit Pravinbhai SEDANI, Kaushikkumar Dhanjibhai PRAJAPATI, Dijixa Pinakin RANA, Sandeep Pankajbhai PATHAK, Japan Nitinkumar DESAI, Jayraj Dilipbhai ARADHYE, Bhavesh Mohanbhai PANCHAL, Indraneel GHOSH, Trinadha Rao CHITTURI
  • SELECTIVE ESTROGEN RECEPTOR DEGRADER
    Publication number: 20210024504
    Abstract: A selective estrogen receptor degrader (SERD), a compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, or pharmaceutically acceptable salts thereof. Also provided are processes for their preparation. Also provided for is the use of these compounds for the treatment of diseases which are related to modulation of estrogen receptors, such as ER-positive breast cancer.
    Type: Application
    Filed: July 22, 2020
    Publication date: January 28, 2021
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Rajan Kumar PAL, Biswajit SAMANTA, Jayraj Dilipbhai ARADHYE, Sandeep Pankajkumar PATHAK, Kaushik Dhanjibhai PRAJAPATI, Bhavesh Mohanbhai PANCHAL, Trinadha Rao CHITTURI
  • Heterocyclic antiestrogens
    Patent number: 10865199
    Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 15, 2020
    Assignee: Sun Pharma Advanced Research Company Limited
    Inventors: Ranjan Kumar Pal, Amit Pravinbhai Sedani, Kaushikkumar Dhanjibhai Prajapati, Dijixa Pinakin Rana, Sandeep Pankajbhai Pathak, Japan Nitinkumar Desai, Jayraj Dilipbhai Aradhye, Bhavesh Mohanbhai Panchal, Indraneel Ghosh, Trinadha Rao Chitturi
  • NOVEL HETEROCYCLIC ANTIESTROGENS
    Publication number: 20180354936
    Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.
    Type: Application
    Filed: October 26, 2016
    Publication date: December 13, 2018
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Ranjan Kumar PAL, Amit Pravinbhai SEDANI, Kaushikkumar Dhanjibhai PRAJAPATI, Dijixa Pinakin RANA, Sandeep Pankajbhai PATHAK, Japan Nitinkumar DESAI, Jayraj Dilipbhai ARADHYE, Bhavesh Mohanbhai PANCHAL, Indraneel GHOSH, Trinadha Rao CHITTURI
  • Dicarboxylic acid derivatives as S1P1 receptor agonists
    Patent number: 8809539
    Abstract: The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: August 19, 2014
    Assignees: Bioprojet, Sun Pharma Advanced Research Company Ltd
    Inventors: Marc Capet, Nicolas Levoin, Isabelle Berrebi-Bertrand, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte, Jayraj Dilipbhai Aradhye, Muthukumaran Natarajan Pillai, Bhavesh Mohanbhai Panchal, Jignesh Kantilal Jivani, Biswajit Samanta, Ranjan Kumar Pal, Rajamannar Thennati